Conference Proceedings

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study.

Kate Manos, Richard Khor, Geoffrey Chong, Jodie Palmer, Michael MacManus, Colm Keane, Andrew M Scott, Jake Shortt, David Ritchie, Leonid Churilov, Laura Johnston, Tom Witkowski, Allison Barraclough, Sze Ting Lee, Wendi Lin, Rachel Koldej, Eliza Hawkes

CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2021

Grants

Awarded by Victorian Cancer Agency


Awarded by Imaginab


Funding Acknowledgements

Victorian Cancer Agency (grant funding -TRP16006), Astra Zeneca (durvalumab and funding), Celgene (funding), Imaginab (<SUP>89</SUP>Zr -Df-IAB22M2C).